Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$6.71	$7.08	$5.28 ▼ $14.38	$551.19M	0.86	454,424 shs	239,398 shs
ENOV Enovis	$32.29 -3.1%	$33.22	$29.13 ▼ $49.83	$1.84B	1.71	829,928 shs	1.07 million shs
LMAT LeMaitre Vascular	$81.37 -2.1%	$83.75	$71.42 ▼ $109.58	$1.84B	0.83	168,489 shs	103,908 shs
NVCR NovoCure	$18.20 +4.8%	$17.38	$14.17 ▼ $34.13	$2.03B	0.74	1.18 million shs	1.43 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	-2.19%	+2.76%	-0.45%	-30.18%	+2.76%
ENOV Enovis	-0.58%	+4.69%	-9.07%	-6.85%	-25.45%
LMAT LeMaitre Vascular	-0.59%	+0.71%	+0.82%	+5.48%	+7.07%
NVCR NovoCure	-5.55%	+3.83%	-6.52%	-13.46%	-18.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	2.5559 of 5 stars	3.3	0.0	0.0	0.0	0.0	4.2	1.3
ENOV Enovis	2.7502 of 5 stars	3.4	2.0	0.0	0.0	1.6	1.7	1.9
LMAT LeMaitre Vascular	2.9573 of 5 stars	2.2	2.0	3.3	0.0	3.1	2.5	1.3
NVCR NovoCure	4.0586 of 5 stars	3.3	4.0	0.0	4.5	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.67	Moderate Buy	$14.33	113.61% Upside
ENOV Enovis	2.80	Moderate Buy	$58.00	79.62% Upside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	20.23% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	80.40% Upside

Current Analyst Ratings Breakdown

Latest BVS, NVCR, LMAT, and ENOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00
4/23/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$42.00 ➝ $34.00
4/16/2025	NVCR NovoCure	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $27.00
4/10/2025	NVCR NovoCure	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $28.00
4/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
4/2/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
3/17/2025	BVS Bioventus	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$567.70M	0.97	$0.53 per share	12.58	$2.80 per share	2.40
ENOV Enovis	$2.15B	0.86	$4.71 per share	6.86	$62.66 per share	0.52
LMAT LeMaitre Vascular	$226.26M	8.13	$1.44 per share	56.52	$13.38 per share	6.08
NVCR NovoCure	$621.71M	3.26	N/A	N/A	$3.39 per share	5.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	-$0.48	N/A	14.59	N/A	-7.11%	15.61%	4.01%	N/A
ENOV Enovis	-$33.26M	-$13.95	N/A	10.12	N/A	-5.95%	4.39%	2.80%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$30.10M	$1.98	44.46	37.50	2.22	19.40%	13.15%	11.47%	7/30/2025 (Estimated)
NVCR NovoCure	-$207.04M	-$1.51	N/A	N/A	N/A	-25.93%	-41.48%	-12.74%	7/24/2025 (Estimated)

Latest BVS, NVCR, LMAT, and ENOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.98%	N/A	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A

Latest BVS, NVCR, LMAT, and ENOV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
ENOV Enovis	0.40	2.27	1.12
LMAT LeMaitre Vascular	N/A	7.74	5.52
NVCR NovoCure	0.27	1.49	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
ENOV Enovis	98.45%
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	32.90%
ENOV Enovis	2.70%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	6.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
ENOV Enovis	6,800	57.12 million	55.49 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable
NVCR NovoCure	1,320	111.49 million	101.40 million	Optionable

BVS, NVCR, LMAT, and ENOV Headlines

Recent News About These Companies

NovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's Why

June 10 at 2:14 PM | marketbeat.com

NovoCure Limited (NASDAQ:NVCR) Receives $32.83 Average Price Target from Analysts

June 7, 2025 | americanbankingnews.com

Wedbush Estimates NovoCure's FY2026 Earnings (NASDAQ:NVCR)

June 7, 2025 | americanbankingnews.com

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

June 6, 2025 | zacks.com

What is Wedbush's Estimate for NovoCure FY2026 Earnings?

June 5, 2025 | marketbeat.com

NovoCure (NASDAQ:NVCR) Sees Strong Trading Volume - Still a Buy?

June 4, 2025 | marketbeat.com

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Analysts

June 4, 2025 | marketbeat.com

NovoCure (NASDAQ:NVCR) Shares Down 8.2% - Should You Sell?

June 3, 2025 | marketbeat.com

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

June 2, 2025 | businesswire.com

Novocure data support pancreatic cancer approval, says Wells Fargo

June 2, 2025 | msn.com

Novocure study shows improved pancreatic cancer survival

June 2, 2025 | massdevice.com

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

June 2, 2025 | aol.com

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025 | businesswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in NovoCure Limited (NASDAQ:NVCR)

May 29, 2025 | marketbeat.com

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

May 28, 2025 | msn.com

Novocure Announces Upcoming Investor Events

May 27, 2025 | finance.yahoo.com

NovoCure Limited (NASDAQ:NVCR) Shares Sold by Two Sigma Investments LP

May 25, 2025 | marketbeat.com

NovoCure Limited (NASDAQ:NVCR) Shares Sold by Voloridge Investment Management LLC

May 24, 2025 | marketbeat.com

Two Sigma Advisers LP Trims Stake in NovoCure Limited (NASDAQ:NVCR)

May 24, 2025 | marketbeat.com

NovoCure: Loading Up On Growth Catalysts

May 24, 2025 | seekingalpha.com

BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, NVCR, LMAT, and ENOV Company Descriptions

Bioventus NYSE:BVS

$6.71 0.00 (0.00%)

As of 04:00 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Enovis NYSE:ENOV

$32.29 -1.05 (-3.15%)

As of 03:58 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

LeMaitre Vascular NASDAQ:LMAT

$81.37 -1.77 (-2.13%)

As of 04:00 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$18.20 +0.84 (+4.84%)

As of 04:00 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time